文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

DROP-IN β探头用于机器人放射性引导手术的首次人体验证:确定最佳信号背景判别算法

First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-20

本研究在7例原发前列腺癌患者中首次人体评估临床级DROP-IN β探头,用于机器人PSMA引导手术中追踪表达PSMA的淋巴结。术中注射1.1 MBq/kg [68Ga]Ga-PSMA,共分析66份淋巴结标本,其中31份(47%)为恶性;优化信号截断算法后,探头对PSMA-PET阳性样本检出率78%,灵敏度76%,特异度93%(对照病理评估)。

要点

  • DROP-IN β探头可在机器人手术中提供自主、高度可操作的示踪剂检测。
  • 优化信号截断算法后,探头对PSMA-PET阳性样本检出率78%、灵敏度76%、特异度93%。
  • 共分析66份淋巴结标本,31份(47%)病理为恶性。

核心结论

  • 本研究首次人体使用DROP-IN β探头,支持将β放射性引导与机器人手术整合。
  • 所达到的灵敏度与特异度具有竞争力,为机器人放射性引导手术打开更广泛的放射性药物应用空间。

研究设计与样本

  • 首次人体验证研究,开发临床级DROP-IN β探头用于检测PET放射性核素(如68Ga)。
  • 纳入7例原发前列腺癌患者,PSMA-PET可见至少1枚淋巴结转移,计划行根治性前列腺切除联合扩大盆腔淋巴结清扫。
  • 手术开始时注射1.1 MBq/kg [68Ga]Ga-PSMA,术中使用β探头在体内追踪表达PSMA的淋巴结。
  • 在本数据集上定义并优化统计软件算法,帮助术者区分来自肿瘤与健康组织的探头信号。

主要发现

  • DROP-IN β探头帮助术者实现自主且高度可操作的示踪剂检测。
  • 体内共分析66份淋巴结标本,其中31份(47%)为恶性。
  • 优化信号截断算法后,探头对PSMA-PET阳性样本检出率为78%,灵敏度76%,特异度93%(对照病理评估)。

关键数值与推荐

  • 患者注射剂量为1.1 MBq/kg [68Ga]Ga-PSMA。
  • 优化信号截断算法后,探头对PSMA-PET阳性样本检出率78%,灵敏度76%,特异度93%(对照病理评估)。
  • 共分析66份淋巴结标本,31份(47%)为恶性。

临床怎么用

  • 本研究为首次人体验证,作者认为DROP-IN β探头支持β放射性引导与机器人手术的整合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In radioguided surgery (RGS), radiopharmaceuticals are used to generate preoperative roadmaps (e.g., PET/CT) and to facilitate intraoperative tracing of tracer avid lesions. Within RGS, there is a push toward the use of receptor-targeted radiopharmaceuticals, a trend that also has to align with the surgical move toward minimal invasive robotic surgery. Building on our initial ex vivo evaluation, this study investigates the clinical translation of a DROP-IN β probe in robotic PSMA-guided prostate cancer surgery. METHODS: A clinical-grade DROP-IN β probe was developed to support the detection of PET radioisotopes (e.g., 68 Ga). The prototype was evaluated in 7 primary prostate cancer patients, having at least 1 lymph node metastases visible on PSMA-PET. Patients were scheduled for radical prostatectomy combined with extended pelvic lymph node dissection. At the beginning of surgery, patients were injected with 1.1 MBq/kg of [68Ga]Ga-PSMA. The β probe was used to trace PSMA-expressing lymph nodes in vivo. To support intraoperative decision-making, a statistical software algorithm was defined and optimized on this dataset to help the surgeon discriminate between probe signals coming from tumors and healthy tissue. RESULTS: The DROP-IN β probe helped provide the surgeon with autonomous and highly maneuverable tracer detection. A total of 66 samples (i.e., lymph node specimens) were analyzed in vivo, of which 31 (47%) were found to be malignant. After optimization of the signal cutoff algorithm, we found a probe detection rate of 78% of the PSMA-PET-positive samples, a sensitivity of 76%, and a specificity of 93%, as compared to pathologic evaluation. CONCLUSION: This study shows the first-in-human use of a DROP-IN β probe, supporting the integration of β radio guidance and robotic surgery. The achieved competitive sensitivity and specificity help open the world of robotic RGS to a whole new range of radiopharmaceuticals.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Collamati F, Morganti S, van Oosterom MN, et al. First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm. Eur J Nucl Med Mol Imaging. 2024. PMID: 38376805. doi:10.1007/s00259-024-06653-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。